Dysglycemia in COVID-19 and Type 2 Diabetes Mellitus: Peculiarities of the Glycemic Profile in Hospitalized Patients and the Role of Steroid-Induced Disorders

BACKGROUND: There is a lack of data on the features of dysglycemia in hospitalized patients with COVID-19 and concomitant diabetes mellitus (DM) confirmed by continuous glucose monitoring (CGM).

AIM: to study the glycemic profile in hospitalized patients with COVID-19 and type 2 diabetes mellitus by continuous glucose monitoring and the role of steroid therapy in dysglycemiadevelopment.

MATERIALS AND METHODS: We examined 21 patients with COVID-19 and DM 2 and 21 patients with DM 2 without COVID-19 (control group) using a professional 4–7-day CGM. We also compared two subgroups of patients with COVID-19 and DM 2: 1) patients received systemic glucocorticosteroids (GCS) during CGM and 2) patients in whomCGMwas performed after discontinuation of GCS.

RESULTS: Compared with controls, patients with COVID-19 and DM2 had lesser values of glycemic «time in range» (32.7 ± 20.40 vs 48.0 ± 15.60%, p = 0.026) andhigher parameters of mean glycemia (p <0.05) but similar proportion of patients with episodes of hypoglycemia (33.3% vs 38.1%, p = 0.75). Patients who received dexamethasone during CGM were characterized by higher hyperglycemia and the absence of episodes of hypoglycemia. In patients who hadCGM after dexamethasone discontinuation, hyperglycemia was less pronounced, but 60% of them had episodes of hypoglycemia, often nocturnal, clinically significant and not detected by routine methods.

CONCLUSION: Patients with COVID-19 and DM 2had severe and persistent hyperglycemia but a third of them hadalso episodes of hypoglycemia. During therapy with dexamethasone, they had the most pronounced hyperglycemia without episodes of hypoglycemia. In patients who underwent CGM after discontinuation of dexamethasone, hyperglycemia was less pronounced but 60% of them have episodes of hypoglycemia, often nocturnal, clinically significant and not diagnosed by routine methods. It would be advisable to recommend at least a 5–6-fold study of the blood glucose level (with its obligatory assessment at night) even for stable patients with COVID-19 and DM 2after the end of GCS treatment.

1. Hussain S, Baxi H, Chand Jamali M, et al. Burden of diabetes mellitus and its impact on COVID-19 patients: A meta-analysis of real-world evidence. Diabetes MetabSyndrClin Res Rev. 2020;14(6):1595-1602. doi: https://doi.org/10.1016/j.dsx.2020.08.014

2. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis.Aging (Albany NY). 2020;12(7):6049-6057. doi: https://doi.org/10.18632/aging.103000

3. Hasan SS, Kow CS, Bain A, et al.Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients. Expert OpinPharmacother. 2021;22(2):229-240. doi: https://doi.org/10.1080/14656566.2020.1837114

4. Zhu L, She Z-G, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. CellMetab. 2020;31(6):1068-1077.e3. doi: https://doi.org/10.1016/j.cmet.2020.04.021

5. Pranata R, Henrina J, Raffaello WM, et al. Diabetes and COVID-19: The past, the present, and the future. Metabolism. 2021;121:154814. doi: https://doi.org/10.1016/j.metabol.2021.154814

6. Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States.J Diabetes Sci Technol. 2020;14(4):813-821. doi: https://doi.org/10.1177/1932296820924469

7. Wu J., Huang J., Zhu G., et al. Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study. BMJ Open Diabetes Res Care.2020;8:1476.doi: https://doi.org/10.1136/bmjdrc-2020-001476

8. Zhang B., Liu S., Zhang L., et al. Admission fasting blood glucose predicts 30-day poor outcome in patients hospitalized for COVID-19 pneumonia. Diabetes ObesMetab.2020;22:1955-1957 doi: https://doi.org/10.1111/dom.14132

9. Zhu B, Jin S, Wu L, et al. J-shaped association between fasting blood glucose levels and COVID-19 severity in patients without diabetes. Diabetes Res ClinPract. 2020;168:108381. doi: https://doi.org/10.1016/j.diabres.2020.108381

10. Hill MA, Mantzoros C, Sowers JR. Commentary: COVID-19 in patients with diabetes. Metabolism. 2020;107:154217. doi: https://doi.org/10.1016/j.metabol.2020.154217

11. Dungan KM, Braithwaite SS, Preiser J-C. Stress hyperglycaemia. Lancet. 2009;373(9677):1798-1807. doi: https://doi.org/10.1016/S0140-6736(09)60553-5

12. Pasquel FJ, Messler J, Booth R, et al. Characteristics of and Mortality Associated With Diabetic Ketoacidosis Among US Patients Hospitalized With or Without COVID-19. JAMANetwOpen. 2021;4(3):e211091. doi: https://doi.org/10.1001/jamanetworkopen.2021.1091

13. Gianchandani R, Esfandiari NH, Ang L, et al. Managing Hyperglycemia in the COVID-19 Inflammatory Storm. Diabetes. 2020;69(10):2048-2053. doi: https://doi.org/10.2337/dbi20-0022

14. Peleg AY, Weerarathna T, McCarthy JS, Davis TME. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. DiabetesMetabResRev. 2007;23(1):3-13. doi: https://doi.org/10.1002/dmrr.682

15. Marfella R, Paolisso P, Sardu C, et al. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Diabetes Metab. 2020;46(5):403-405. doi: https://doi.org/10.1016/j.diabet.2020.05.005

16. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a metaanalysis. ProgCardiovasc Dis. 2020;63(3):390-391. doi: https://doi.org/10.1016/j.pcad.2020.03.001

17. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020;141(20):1648-1655. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.046941

18. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMACardiol. 2020;5(7):802-810. doi: https://doi.org/10.1001/jamacardio.2020.0950

19. Rayman G, Lumb AN, Kennon B, et al. Dexamethasone therapy in COVID‐19 patients: implications and guidance for the management of blood glucose in people with and without diabetes. DiabetMed. 2021;38(1):78-80. doi: https://doi.org/10.1111/dme.14378

20. Ushigome E, Yamazaki M, Hamaguchi M, et al. Usefulness and Safety of Remote Continuous Glucose Monitoring for a Severe COVID-19 Patient with Diabetes. DiabetesTechnolTher. 2021;23(1):78-80. doi: https://doi.org/10.1089/dia.2020.0237

21. U.S. Food and Drug Administration[Internet]. FAQs on home-use blood glucose meters utilized within hospitals during the COVID-19 pandemic. [cited 2020 Apr 23]. Available from: https://www.fda.gov/medical-devices/blood-glucosemonitoring-devices/faqs-home-use-blood-glucose-meters-utilizedwithin-hospitals-during-covid-19-pandemic

22. Sadhu AR, Serrano IA, Xu J, et al. Continuous Glucose Monitoring in Critically Ill Patients With COVID-19: Results of an Emergent Pilot Study. J DiabetesSciTechnol. 2020;14(6):1065-1073. doi: https://doi.org/10.1177/1932296820964264

23. Agarwal S, Mathew J, Davis GM, et al. Continuous Glucose Monitoring in the Intensive Care Unit During the COVID-19 Pandemic. DiabetesCare. 2021;44(3):847-849. doi: https://doi.org/10.2337/dc20-2219

24. Davis GM, Faulds E, Walker T, et al. Remote Continuous Glucose Monitoring With a Computerized Insulin Infusion Protocol for Critically Ill Patients in a COVID-19 Medical ICU: Proof of Concept. DiabetesCare. 2021;44(4):1055-1058. doi: https://doi.org/10.2337/dc20-2085

25. Chow KW, Kelly DJ, Rieff MC, et al. Outcomes and Healthcare Provider Perceptions of Real-Time Continuous Glucose Monitoring (rtCGM) in Patients With Diabetes and COVID-19 Admitted to the ICU. J DiabetesSciTechnol. 2021;15(3):607-614. doi: https://doi.org/10.1177/1932296820985263

26. Anciferov MB, Andreeva AV, Markova TN. Organizacija specializirovannoj medicinskoj pomoshhi vzroslomu naseleniju s saharnym diabetom v uslovijah novoj koronavirusnoj infekcii COVID-19. Metodicheskie rekomendacii №87. Moscow: DepartamentzdravoohranenijagorodaMoskvy; 2020. 50 p. (In Russ.).

27. Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. DiabetesCare. 2017;40(12):1631-1640. doi: https://doi.org/10.2337/dc17-1600

28. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603. doi: https://doi.org/10.2337/dci19-0028